Facebook Twitter LinkedIn Google Plus RSS

NJII introduces immunotherapy training for biopharma companies

By ,
Dr. Donald Sebastian, president, New Jersey Innovation Institute
Dr. Donald Sebastian, president, New Jersey Innovation Institute - ()

The New Jersey Innovation Institute has launched a training program for biopharmaceutical companies to study new immunotherapies, such as CAR-T cell therapy.

Immunotherapy generally is a treatment in which cells in the human body are recoded and injected back into a patient in order to train the patient’s immune system to fight various diseases such as cancer. Cancer centers such as Hackensack Meridian Health’s John Theurer Cancer Center and Memorial Sloan Kettering, and pharmaceutical giants including Celgene and Johnson & Johnson have made big bets on the treatment.

The workforce training program is in response to increasing demands from the biopharmaceutical industry for engineers and scientists to be trained in manufacturing and processing of the newest breakthroughs in biologic and immunotherapies such as advanced CAR-T therapy.

The program will combine lectures and hands-on training to introduce the newest approaches and technologies applied to the development and production of these innovative therapies.

 “The pharmaceutical industry faces formidable challenges as it adapts to the new culture of biotechnology,” said NJII CEO Donald Sebastian, during NJII’s Annual Innovation Summit in Newark on March 15. “This training initiative demonstrates NJII’s commitment to advance cell and gene therapy manufacturing and processing innovation.”

You May Have Missed...

Vince Calio

Vince Calio

Vince Calio covers health care and manufacturing for NJBIZ. You can contact him at vcalio@njbiz.com.

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy